|
1
|
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
|
Cancer Res
|
2009
|
1.38
|
|
2
|
Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase.
|
Bioorg Med Chem Lett
|
2007
|
1.30
|
|
3
|
Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus.
|
J Virol
|
2010
|
1.27
|
|
4
|
Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase.
|
Bioorg Med Chem Lett
|
2006
|
1.12
|
|
5
|
Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure.
|
Bioorg Med Chem Lett
|
2006
|
0.97
|
|
6
|
Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.
|
Antimicrob Agents Chemother
|
2013
|
0.87
|
|
7
|
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
|
Antivir Chem Chemother
|
2004
|
0.87
|
|
8
|
Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors.
|
Bioorg Med Chem Lett
|
2006
|
0.82
|
|
9
|
Pharmacological disruption of hepatitis C NS5A protein intra- and intermolecular conformations.
|
J Gen Virol
|
2013
|
0.82
|
|
10
|
Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.
|
J Med Chem
|
2014
|
0.82
|
|
11
|
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
|
Liver Int
|
2013
|
0.81
|
|
12
|
In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
|
Antimicrob Agents Chemother
|
2013
|
0.79
|
|
13
|
Hepatitis C genotype 1a replicon improved through introduction of fitness mutations.
|
Biotechniques
|
2012
|
0.79
|
|
14
|
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
|
J Med Chem
|
2013
|
0.78
|
|
15
|
Isothiazoles as active-site inhibitors of HCV NS5B polymerase.
|
Bioorg Med Chem Lett
|
2006
|
0.78
|
|
16
|
Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.
|
Liver Int
|
2014
|
0.78
|
|
17
|
Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors.
|
Bioorg Med Chem Lett
|
2006
|
0.78
|
|
18
|
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
|
J Med Chem
|
2012
|
0.76
|
|
19
|
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
|
Bioorg Med Chem Lett
|
2012
|
0.75
|
|
20
|
Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors.
|
Bioorg Med Chem Lett
|
2006
|
0.75
|
|
21
|
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
|
Bioorg Med Chem Lett
|
2012
|
0.75
|